Mind Medicine MindMed Inc (MNMD) Quote

Ha! Just popped up on StockTwits

Nice stair stepping

Trump administration exploring potential benefits of psychedelic treatments

Fox News correspondent Alexandria Hoff discusses the Trump administration’s stances on psychedelic treatments on ‘America’s Newsroom.’

https://www.foxnews.com/video/6373914669112

Currently speaking at Jefferies Conference. This space is going to be like when AI hit. This is a big deal!

"In connection with her appointment as Chief Financial Officer on June 2, 2025, MindMed will grant Ms. Roberts on such date inducement awards consisting of (i) an option to purchase 500,000 common shares of the Company (the "Option") and (ii) 125,000 performance share units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting."

That's a nice carrot to perform.

Also, Lundbeck acquired Longboard Pharmaceuticals while they were in Phase III trials also. Read that PR here... some similar parallels... they had other products, but the PR was heaviliy directed at the drug candidate in Phase 3.

Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline - https://www.lundbeck.com/us/newsroom/2024/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal)

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

https://ir.mindmed.co/news-events/press-releases/detail/184/mindmed-strengthens-executive-team-with-appointment-of-brandi-roberts-cpa-as-chief-financial-officer

This is where the tide starts to shift. :)

Good find. Great things are coming.

Beyond excellent.

Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors

https://www.benzinga.com/markets/cannabis/25/05/45601096/ex-govt-foe-joins-trump-rfk-jr-s-hhs-to-lead-psychedelics-policy-what-it-means-for-investors?utm_source=articleShare

POLITICSLawyer Who Sued Federal Health Agency Over Marijuana Rescheduling Will Now Work There, With Focus On Psychedelics

https://www.marijuanamoment.net/lawyer-who-sued-federal-health-agency-to-release-marijuana-documents-now-works-there-with-focus-on-psychedelics/

This is huge for the sector. Lock your shares. This will now officially heat up. Wow.

This article featuring Mindmed popped into my email notifications for Medscape articles I subscribe to.

https://www.medscape.com/viewarticle/lsd-anxiety-and-depression-worth-trip-2025a1000b24?ecd=mkm_ret_250524_mscpmrk_psych_depress_etid7440784&uac=129766SJ&impID=7440784

RBC Meeting Notes:

Synopsis of the RBC Capital Markets Interview with MindMed (MNMD), focused on key facts about the company, its clinical pipeline, regulatory progress, commercialization efforts, and R&D beyond its lead program.

Clinical Pipeline Highlights

1. MM120 – Generalized Anxiety Disorder (GAD)

Lead Candidate: MM120 (LSD D-tartrate formulation)

Indication: Generalized Anxiety Disorder (GAD)

Phase: Phase 3 (Voyage and Panorama studies)

Design & Powering:

90% power to detect a 5-point difference between 100µg dose and placebo (primary analysis).

Sample Size: 100 patients per arm, allowing for a standard deviation of 10 and a 10–15% non-evaluable rate.

Adaptive Design: Includes interim sample size re-estimation based on standard deviation and dropout rates (not on effect size) to maintain 90% power.

Extension Study:

Open-label phase with up to 4 treatments allowed.

Entry HAMD score threshold: 16 (vs. 20 for initial trial).

Double-blind period allows continued analysis of single-dose durability.

2. MM120 – Major Depressive Disorder (MDD)

Indication: Major Depressive Disorder

Phase: Phase 2b (“EMerge” study)

Operational Synergies: Shared recruitment sites with GAD trials help improve patient screening and enrollment efficiency.

Cross-eligibility Logic: Patients diagnosed with MDD but not experiencing an episode may qualify for the GAD trial, improving enrollment flexibility.

Regulatory Strategy & FDA Engagement

Breakthrough Therapy Designation: Accelerates development and review.

FDA Relationship: Positive, consistent, and collaborative for over 5 years.

Guidance Trend: No recent changes; FDA engagement has remained stable despite personnel turnover.

Regulatory Philosophy: MindMed emphasizes that while psychedelics are novel, the approach is grounded in precedents (e.g., anesthesia, interventional psychiatry) to reduce regulatory resistance.

Commercialization Strategy

U.S. Focus

Chief Commercial Officer: Matt Wiley (noted for handling complex launches).

Target Channels:

Existing interventional psychiatry clinics (4,000–5,000+ in the U.S.).

Bravado and TMS clinics are natural launch candidates.

Individual therapy offices could serve as session monitoring sites.

Infrastructure Needs

Minimal Physiological Monitoring: No need for vital signs monitoring reduces complexity.

Psychological Monitoring: Only requires supportive presence (no structured psychotherapy needed).

Reimbursement: Will leverage existing CPT/HCPCS codes; sessions billed under E/M and monitoring time codes.

Payer Strategy: Active engagement in payer education and contracting is underway.

Europe

Current Focus: Primarily on U.S. commercialization.

European Strategy: Active regulatory and development discussions ongoing to prepare for future expansion.

Market Need & Societal Support

Broad Governmental Interest: Strong bipartisan and multi-level (federal, state, local) support.

Public Health Urgency: Widespread recognition of the unmet need in anxiety and depressive disorders.

Advocacy Message: Framed to policymakers as a familiar medical approach rather than a radical new paradigm.

Early-Stage Program: R(-)-MDMA (R-MDMA)

Indication: Autism Spectrum Disorder (ASD)

Target Mechanism: Selective serotonin release (vs. dopaminergic activity in racemic MDMA)

Rationale: Enhanced prosocial behavior and emotional resonance.

Preclinical Results: Encouraging efficacy and safety profile.

Phase 1 (Single Ascending Dose): Successfully completed.

Next Step: Early Signal of Efficacy (ESE) study designed to measure improvement in:

Social behavior

Empathy

Communication

RBC Meeting for MindMed happening now.

https://kvgo.com/rbc/mind-medicine-inc-may-2025

Looking real sweet today 

Gearing up for the inevitable.

MindMed Announces New Employee Inducement Grants

This is bullish

https://www.businesswire.com/news/home/20250519674150/en

FDA commissioner says research on psychedelic treatment ‘top priority' | On Balance

https://www.youtube.com/watch?v=KEQFKBME668

We know this to be true.

Our time is coming.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

https://insights.citeline.com/in-vivo/leadership/rising-leaders/rising-leaders-2025-rob-barrow-on-leading-mindmeds-psychedelic-renaissance-J5TLUOIOIJFUHPWMQS2PRGYPOE/

I wouldn't say that. Could have been the Form D filing, but that is not a bad thing. We're good. This is the final stretch.

Added here @ 6.81.

I must be a glutton for punishment lol

Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

https://finance.yahoo.com/news/institutional-investors-own-significant-stake-123730402.html

Nice catch!

https://www.11alive.com/article/news/politics/va-sec-doug-collins-says-agency-will-look-at-psychedelic-other-alternative-treatments/85-d90e6b9d-a705-4f09-aeda-5b839879bd03

Secretary of VA Collins mentioned yesterday in the 100 day cabinet meeting that evaluating psychedelic treatment for vets is a main focus. A lot of eyes were on this meeting.

Nice block acquired there.

Not concerned. I know we will be. This will be some of the biggest headlines when it happens.

We're going to be on the better side of history with this 

No, that is still very much in play.

This was the final stretch we've waited for. Hang tight. We have arrived. Let it steep. We are in for a strong ramp once CMSP read outs happen in June. Once that happens. Organic rise to the big wave.

Wait! A couple of more years?

So, I guess the $30-$40 billlion buyout by this June that you predicted is off the table? Imagine that! LMAO

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173524304

Looks like you're in for another ENZC ride here, Jack! lol How did holder yer shares work out for you there?

You've learned nothing from that, obviously!

It's gonna be a good next couple years. MM120 is gonna be approved, probably for both conditions. This will lead to other approvals down the road.

HOLD YER SHARES!!!

MindMed’s Bet on Psychedelic Psychiatry: Vanguards of Health Care

https://www.bloomberg.com/news/audio/2025-04-24/mindmed-s-bet-on-psychedelic-therapy-vanguards-of-health-care?srnd=homepage-americas

Check out this: https://www.reddit.com/r/MindMedInvestorsClub/comments/1k6g4ae/mnmd_schedule_14a_information_proxy_statement/

MNMD - SCHEDULE 14A INFORMATION - Proxy Statement Notes

Skimming through the new proxy (14A) from MindMed, I noticed something worth sharing, especially for those of us watching for long-term value or potential M&A action.

In Proposal No. 3 (page 34), which outlines the 2025 Equity Incentive Plan, there’s a line that stood out:

“A ‘liberal’ change in control definition (e.g., mergers require actual consummation) is not included.”

What this means in plain English: MindMed is using a stricter definition of “Change in Control.” Executives don’t get perks just because a deal is announced or a merger agreement is signed. They only benefit if and when the deal actually closes.

This is known as avoiding a “liberal” change in control definition. More liberal definitions let insiders cash in early — like just from a signed agreement or a change in board seats. That’s not the case here.

Instead, MindMed is requiring actual completion of a merger or acquisition before any bonuses or early stock vesting kick in. This protects investors from dilution or executive windfalls tied to deals that never even happen.

Why this matters (especially for retail investors like us):

It avoids premature executive payouts.

It shows smart governance — aligning leadership incentives with real shareholder value.

It might be a sign the company is positioning itself for possible future interest (acquisition, partnership, etc.), but doing it the right way.

To be clear — this doesn’t guarantee an M&A deal is coming. But it’s the kind of language that often appears when a company is tightening up its structure in preparation for something. Could be Phase 3 momentum, could be something bigger. Either way, the setup is solid.

Bottom line: This is investor-friendly language. And it’s refreshing to see a microcap biotech doing things by the book, instead of padding exec pay with low bars. Worth keeping an eye on.

MNMD is now considered a late Stage bio company. Hold. We are close.

All 3 Phase 3 Trials are active. Let's ride!

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

https://www.businesswire.com/news/home/20250414503827/en/MindMed-Announces-First-Patient-Dosed-in-Phase-3-Emerge-Study-of-MM120-in-Major-Depressive-Disorder-MDD

I am not a fan of what is going on. No one is really. However, there are some silver linings here.

Despite concerns around potential pharmaceutical tariffs, these recent developments might actually create significant opportunities for companies like MindMed. Rather than negatively impacting the sector, tariffs could reshape the pharmaceutical landscape in ways that positively benefit innovative, US-focused firms.

Key points highlighting the positive potential for MindMed include:

Enhanced Investment Flow: European uncertainty could redirect substantial pharma capital to the U.S., boosting investor interest and financial backing for innovative American biotech firms like MindMed.
Reduced Competition: Tariffs could discourage European competitors from quickly expanding into the U.S., giving MindMed more space and time to establish leadership in novel therapeutic areas.

Improved Industry Environment: Increased domestic pharmaceutical activity could lead to stronger industry infrastructure, talent availability, and accelerated regulatory support, benefiting MindMed’s product development and commercialization efforts.

Ultimately, rather than succumbing to tariff-related fear, uncertainty, and doubt (FUD), investors might recognize this as an opportunity for MindMed to strengthen its competitive advantage and benefit from renewed focus and investment in U.S.-based pharmaceutical innovation.

its margin calls

Yes, Mom, it has nothing directly to do with MNMD but it is crushing our stock price. Good luck with your catch a falling knife philosophy. This stock was struggling before Depression Don worked his magic and has only accelerated downward since.

What is happening is not good for any developmental biotech.

It's fear.

This has nothing to do with MindMed... f anything all this makes them more valuable. The economy is tanking due to the administration. I got a nice chuck at down on that giant dip.

people are forced to sell what is liquid

I don’t know about y’all but I’m getting tired of all this winning.

Synergistic air pollution exposure elevates depression risk: A cohort study

Depression is a leading mental health disorder worldwide, contributing substantially to the global disease burden. While emerging evidence suggests links between specific air pollutants and depression, the potential interactions among multiple pollutants remain underexplored. Here we show the influence of six common air pollutants on depressive symptoms among middle-aged and older Chinese adults. In single-pollutant models, a 10 mgm3 increase in SO2, CO, PM10, and PM2.5 is associated with increased risks of depressive symptoms, with odds ratios (95% confidence intervals) of 1.276 (1.238e1.315), 1.007 (1.006e1.008), 1.066 (1.055e1.078), and 1.130 (1.108e1.153), respectively. In two-pollutant models, SO2 remains significantly associated with depressive symptoms after adjusting for other pollutants. Multipollutant models uncover synergistic effects, with SO2, CO, NO2,PM10,andPM2.5 exhibiting significant interactions, identifying SO2 as the primary driver of these associations. Mediation analyses further indicate that cognitive and physical impairments partially mediate the relationship between air pollution and depressive symptoms. These findings underscore the critical mental health impacts of air pollution and highlight the need for integrated air quality management strategies. Targeted mitigation of specific pollutants, particularly SO2, is expected to significantly enhance public mental health outcomes. ©2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Society for Environmental Sciences, Harbin Institute of Technology, Chinese Research Academy of Environmental Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Trump Stalls Cannabis Reform, Plus Mindmed CEO's 2025 Outlook | Trade to BLack - Dale's Report

Doug Collins - United States Secretary of Veterans Affairs | SRS #187

Trump’s Veterans Secretary Had ‘Eye-Opening’ Psychedelics Talk With RFK Jr.—And He Plans To Press Congress To Act

https://www.marijuanamoment.net/trumps-veterans-secretary-had-eye-opening-psychedelics-talk-with-rfk-jr-and-he-plans-to-press-congress-to-act/